Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2025-10-21
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in
relapsed/refractory Acute Myeloid Leukemia (AML).
The clinical study is to evaluate the safety, tolerability and preliminary efficacy of
QN-023a in patients with relapsed/refractory AML,where a "3+3" enrollment schema will be
utilized at dose escalation stage. Up to 18 patients will be enrolled.